| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/17/2014 | WO2014057727A1 Method for manufacturing substance containing nobiletin and tangeretin derived from citrus fruits, and nobiletin- and tangeretin-containing substance obtained thereby |
| 04/17/2014 | WO2014057687A1 Antibody-drug conjugate |
| 04/17/2014 | WO2014057511A1 Use of emicorons as selective inducers of damage to the telomere dna |
| 04/17/2014 | WO2014057266A1 Acylpiperazines as inhibitors of transglutaminase and their use in medicine |
| 04/17/2014 | WO2014057122A1 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| 04/17/2014 | WO2014057119A1 Pyrrolobenzodiazepine-antibody conjugates |
| 04/17/2014 | WO2014057118A1 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| 04/17/2014 | WO2014057117A1 Pyrrolobenzodiazepine-antibody conjugates |
| 04/17/2014 | WO2014057115A1 Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
| 04/17/2014 | WO2014057114A1 Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| 04/17/2014 | WO2014057113A1 Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| 04/17/2014 | WO2014057074A1 Pyrrolobenzodiazepines and conjugates thereof |
| 04/17/2014 | WO2014057073A1 Pyrrolobenzodiazepines and conjugates thereof |
| 04/17/2014 | WO2014057067A1 Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| 04/17/2014 | WO2014056897A1 Combination of opioids and anticancer drugs for cancer treatment |
| 04/17/2014 | WO2014056871A1 Azaindolines |
| 04/17/2014 | WO2014056867A1 Azaindolines |
| 04/17/2014 | WO2014056755A1 Indolines |
| 04/17/2014 | WO2014056627A1 Novel approaches for individualized therapy of pancreatic ductal adenocarcinoma |
| 04/17/2014 | WO2014056566A1 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
| 04/17/2014 | WO2014056446A1 Phenyl 1,2-isoxazolyl or phenyl 1,2-pyrazole compound and application thereof |
| 04/17/2014 | WO2014056422A1 hnRNP A2* PROTEIN, NUCLEIC ACID FOR CODING PROTEIN AND USE THEREOF |
| 04/17/2014 | WO2014056414A1 Reduction stimuli-responsive gene vector system and preparation and use thereof |
| 04/17/2014 | WO2014056401A1 Double-bond substituted tripterygium wilfordii lactone derivative and preparation method and use thereof |
| 04/17/2014 | WO2014056396A1 Flumatinib mesylate crystal form and preparation method and use thereof |
| 04/17/2014 | WO2014056333A1 Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor |
| 04/17/2014 | WO2014056304A1 Cisplatin complex and preparation method thereof |
| 04/17/2014 | WO2014056270A1 Targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof |
| 04/17/2014 | WO2014056083A1 Kinase inhibitors and method of treating cancer with same |
| 04/17/2014 | WO2014036556A3 Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine |
| 04/17/2014 | WO2014030142A3 Nitroimidazole compounds and their use in cancer therapy |
| 04/17/2014 | WO2014029888A3 Branched or macrocyclic polyamines and uses thereof |
| 04/17/2014 | WO2014028461A3 Treatment and diagnosis of melanoma |
| 04/17/2014 | WO2014018673A3 Fusion proteins and methods thereof |
| 04/17/2014 | WO2013061004A8 Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases |
| 04/17/2014 | WO2013006619A9 Rna-yy1 interactions |
| 04/17/2014 | US20140107391 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 04/17/2014 | US20140107169 Parenteral formulation for epothilone analogs |
| 04/17/2014 | US20140107125 Hydrazonopyrazole derivatives and their use as therapeutics |
| 04/17/2014 | US20140106456 Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material |
| 04/17/2014 | US20140106450 Compositions and Methods for Inhibiting Expression of a Target Gene |
| 04/17/2014 | US20140105992 Vaccine |
| 04/17/2014 | US20140105895 Treatment of solid tumors with rapamycin derivatives |
| 04/16/2014 | EP2719699A1 Certain triazolopyrazines, compositions thereof and methods of use therefor |
| 04/16/2014 | EP2719698A1 Methods for preparing aurora kinase inhibitors |
| 04/16/2014 | EP2719697A1 Pyridonaphthyridine pi3k/mtor dual inhibitors and preparation and use thereof |
| 04/16/2014 | EP2719696A1 Novel kinase inhibitors |
| 04/16/2014 | EP2719392A1 Suppression of neuroendocrine diseases |
| 04/16/2014 | EP2719375A1 Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| 04/16/2014 | EP2718457A1 Engineered antibody-tnfsf member ligand fusion molecules |
| 04/16/2014 | EP2718438A1 Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy |
| 04/16/2014 | EP2718436A1 Materials and methods for treating pten mutated or deficient cancer |
| 04/16/2014 | EP2718435A1 Sema5b peptides and vaccines including the same |
| 04/16/2014 | EP2718427A1 Compositions and methods for glioblastoma treatment |
| 04/16/2014 | EP2718297A2 New taccalonolide microtubule stabilizers |
| 04/16/2014 | EP2718296A1 Synthesis and characterization of second generation benzofuranone ring substituted noscapine analogs |
| 04/16/2014 | EP2718293A1 Substituted pyridopyrazines as novel syk inhibitors |
| 04/16/2014 | EP2718292A1 Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
| 04/16/2014 | EP2718282A1 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
| 04/16/2014 | EP2718276A1 Heterocyclic sulfonamide derivatives |
| 04/16/2014 | EP2718270A2 Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| 04/16/2014 | EP2717925A1 Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof |
| 04/16/2014 | EP2717917A1 P97-antibody conjugates and methods of use |
| 04/16/2014 | EP2717916A1 Protein-polymer-drug conjugates |
| 04/16/2014 | EP2717913A2 Monoclonal antibody and antigens for diagnosing and treating lung disease and injury |
| 04/16/2014 | EP2717912A1 Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer |
| 04/16/2014 | EP2717911A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| 04/16/2014 | EP2717907A1 Use of photolyase for reducing or improving subclinical field cancerization associated with actinic keratosis |
| 04/16/2014 | EP2717901A2 He4 based therapy for malignant disease |
| 04/16/2014 | EP2717897A2 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
| 04/16/2014 | EP2717887A2 Methods for treating or preventing graft versus host disease |
| 04/16/2014 | EP2717886A1 Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism |
| 04/16/2014 | EP2717885A1 Antiinfective composition |
| 04/16/2014 | EP2717884A1 Use of metallocene compounds for cancer treatment |
| 04/16/2014 | EP2717875A2 Bisacodyl and analogues as drugs for treating cancer |
| 04/16/2014 | EP2717870A1 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| 04/16/2014 | EP2717869A2 Methods of treatment using a bcat1 inhibitor |
| 04/16/2014 | EP2717866A2 Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| 04/16/2014 | EP2717865A2 Methods and compositions for treating brain cancer |
| 04/16/2014 | EP2717856A2 Ceramide anionic liposome compositions |
| 04/16/2014 | CN103732746A Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia |
| 04/16/2014 | CN103732743A Mphosph1 peptides and vaccines including the same |
| 04/16/2014 | CN103732739A Recombinant adenovirus comprising trans-splicing ribozyme and cancer-treating gene, and use thereof |
| 04/16/2014 | CN103732612A NOTCH pathway signaling inhibitor compound |
| 04/16/2014 | CN103732596A Novel pyrrolo pyrimidine derivatives |
| 04/16/2014 | CN103732595A Folate conjugates of albumin-binding entities |
| 04/16/2014 | CN103732592A Insulin-like growth factor-1 receptor inhibitors |
| 04/16/2014 | CN103732589A Substituted sulfonamides useful as antiapoptotic BCL inhibitors |
| 04/16/2014 | CN103732588A Spirocyclic molecules as protein kinase inhibitors |
| 04/16/2014 | CN103732586A Acetyltanshinone IIA (ATA) as anticancer agent |
| 04/16/2014 | CN103732577A New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments |
| 04/16/2014 | CN103732253A Use of small molecules in methods for purification of biomolecules |
| 04/16/2014 | CN103732247A Methods for handling biological drugs containing living cells |
| 04/16/2014 | CN103732229A Method for treating cancer by combined use of medicinal agents |
| 04/16/2014 | CN103732226A mTOR/JAK inhibitor combination therapy |
| 04/16/2014 | CN103732221A Gallium complexes, pharmaceutical compositions and methods of use |
| 04/16/2014 | CN103728294A Applications of bisbenzimidazole bicarbazole compound in specific binding nucleic acid G-quadruplex structure and anti-tumor drug |
| 04/16/2014 | CN103725791A Egfr inhibitor treatment marker |
| 04/16/2014 | CN103725682A Small interfering ribonucleic acid (RNA) for knocking down expression of estrogen related receptor (ERR), and recombinant vector and application of RNA |
| 04/16/2014 | CN103724432A Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) |